Trevogrumab
Regeneron's antibody against myostatin (GDF8) — the third horse in the muscle-preservation race. Being trialled alongside semaglutide, alone and paired with a second antibody, to keep weight loss from eating your muscle.
What people claim
Add it to a GLP-1 and the weight you lose is fat, not muscle.
Human evidence
Real but earliest-stage of the three. Trevogrumab has been through earlier human studies (including in sarcopenia), and Regeneron's phase 2 COURAGE trial pairs it with semaglutide — with reported interim results suggesting meaningfully better lean-mass preservation during GLP-1 weight loss. Interim phase 2 is the definition of 'promising, unproven': the full data and larger trials decide whether this holds.
Animal evidence
The same deep myostatin biology as its cousins — blocking GDF8 reliably grows muscle in animals. Regeneron's genetics-first approach is built on that pathway being one of the best-validated muscle targets in biology.
Risk flags
- Long-term effects unknown
- Unregulated / grey-market supply
- Purity & quality unknowable
- Banned in tested sport (WADA)
Regulatory status
US: Investigational. NOT FDA-approved; in phase 2 trials for muscle preservation during weight loss.
UK: Investigational; no MHRA authorisation.
Everyone's an expert
Who says what
Gym Bros Say
"Regeneron's answer to Lilly's bimagrumab. Whoever wins, we get to keep our gains while cutting."
Reddit Says
Discussed mostly in 'GLP-1 muscle loss' threads as the third contender, usually alongside warnings that none of the three can be legitimately bought.
Big Pharma Says
Regeneron is explicitly chasing the muscle-preservation-plus-GLP-1 combination — including a trial arm that adds a second antibody (garetosmab, anti-activin A) on top. Big pharma believes in this category enough to run multi-antibody trials.
Science Actually Says
Grade C: earlier human studies plus encouraging interim phase 2 data in combination with semaglutide. Less published human evidence than bimagrumab or apitegromab so far — which is a statement about timing, not about the target.
PeptideStackers Says
Promising, early, and unobtainable — the trifecta that grey-market grifters love. Same warning as its cousins: a monoclonal antibody cannot come out of a peptide-synthesis lab, so 'trevogrumab for sale' is a scam by definition.
Honesty section
What we still don't know
- ?The full COURAGE results — interim readouts can shift.
- ?Whether preserved lean mass means preserved strength and function.
- ?Long-term safety of chronic myostatin blockade, alone or with an activin blocker stacked on top.
- ?How it compares head-to-head with bimagrumab and apitegromab (nobody has run that trial).
Real questions people ask
FAQ
- What is trevogrumab?
- A monoclonal antibody from Regeneron that blocks myostatin (GDF8), the protein that limits muscle growth. It's in phase 2 trials combined with semaglutide, aiming to preserve muscle during GLP-1 weight loss. It is not approved anywhere.
- Trevogrumab vs bimagrumab — what's the difference?
- Different targets on the same pathway: trevogrumab binds myostatin itself, bimagrumab blocks the receptor (ActRII) that myostatin and friends signal through. Blocking the receptor is the broader intervention. Nobody has compared them head-to-head in a trial.
- Can you buy trevogrumab?
- No — and be especially suspicious here. Antibodies require living-cell manufacturing and cold-chain handling that grey-market vendors simply do not have. Anything sold under this name is near-certainly not the real molecule.
Before you do anything
Questions to ask a qualified professional
- 01What does the evidence actually support today for keeping muscle during weight loss?
- 02If several muscle-preservation drugs reach approval, how would a clinician choose between them?
- 03What would make me trust an interim trial readout — and what should make me wait for the full data?